美国 · SEC FORM 4
Caris Life Sciences, Inc.
CAI · Nasdaq · CIK 0002019410 · Healthcare · Biotechnology
内部人信号
2 qualifying P purchase groups
当前 180 天评分窗口
25 同一窗口内观察到的 Form 4 交易行
5 sales · 18 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 9 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-05-15 · HALBERT JON.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 13,891,975
- 上期报告
- 13,331,431
- 日均成交量
- 5,592,020
- 回补天数
- 2.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | HALBERT JON | 买入 (P) | Common Stock | 68,000 | USD 14.56 | USD 990,080 | SEC 申报 ↗ |
| 2026-05-11 | Vacirca Jeff L | 买入 (P) | Common Stock | 31,050 | USD 16.15 | USD 501,457 | SEC 申报 ↗ |
| 2025-11-07 | Spetzler David Baxley | 买入 (P) | Common Stock | 400 | USD 23.85 | USD 9,540 | SEC 申报 ↗ |
| 2025-11-07 | Denton John Russel | 买入 (P) | Common Stock | 4,184 | USD 24.09 | USD 100,793 | SEC 申报 ↗ |
| 2025-06-20 | Denton John Russel | 买入 (P) | Common Stock | 7,500 | USD 21.00 | USD 157,500 | SEC 申报 ↗ |
| 2025-06-20 | Brille Brian J | 买入 (P) | Common Stock | 30,000 | USD 21.00 | USD 630,000 | SEC 申报 ↗ |
Form 4 申报证据
45 transaction lines in the latest 365-day window; 80 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | Denton John Russel | 卖出 (S) | Common Stock | 7,500 | USD 31.82 | USD 238,650 | SEC 申报 ↗ |
| 2026-09-17 | Brille Brian J | 卖出 (S) | Common Stock | 400,000 | USD 30.33 | USD 12,132,000 | SEC 申报 ↗ |
| 2026-09-17 | Brille Brian J | 期权行权／转换 (M) | Common Stock | 400,000 | USD 2.44 | USD 976,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | Denton John Russel | 卖出 (S) | Common Stock | 7,500 | USD 31.82 | USD 238,650 | SEC 申报 ↗ |
| 2026-09-17 | Brille Brian J | 卖出 (S) | Common Stock | 400,000 | USD 30.33 | USD 12,132,000 | SEC 申报 ↗ |
| 2026-09-17 | Brille Brian J | 期权行权／转换 (M) | Common Stock | 400,000 | USD 2.44 | USD 976,000 | SEC 申报 ↗ |
| 2026-09-04 | Spetzler David Baxley | 卖出 (S) | Common Stock | 119,212 | USD 24.76 | USD 2,951,689 | SEC 申报 ↗ |
| 2026-09-04 | Spetzler David Baxley | 期权行权／转换 (M) | Common Stock | 250,000 | USD 2.44 | USD 610,000 | SEC 申报 ↗ |
| 2026-09-03 | Spetzler David Baxley | 卖出 (S) | Common Stock | 478,000 | USD 24.86 | USD 11,882,824 | SEC 申报 ↗ |
| 2026-09-03 | Spetzler David Baxley | 期权行权／转换 (M) | Common Stock | 1,000,000 | USD 2.44 | USD 2,440,000 | SEC 申报 ↗ |
| 2026-08-14 | Vacirca Jeff L | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | PHILLIPS T DANNY | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Minor Lloyd | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | JOHANSEN LAURA I | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | HALBERT JON | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Gilliam Joseph E | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Fredrickson David Paul | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | CASTLEMAN PETER M | 奖励／授予 (A) | Common Stock | 13,192 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-29 | POSTE GEORGE | 奖励／授予 (A) | Common Stock | 1,600 | USD 15.62 | USD 24,992 | SEC 申报 ↗ |
| 2026-05-29 | Knowles Jonathan Kenneth Charles | 奖励／授予 (A) | Common Stock | 1,600 | USD 15.62 | USD 24,992 | SEC 申报 ↗ |
| 2026-05-15 | HALBERT JON | 买入 (P) | Common Stock | 68,000 | USD 14.56 | USD 990,080 | SEC 申报 ↗ |
| 2026-05-15 | Spetzler David Baxley | 代扣税 (F) | Common Stock | 13,856 | USD 15.25 | USD 211,304 | SEC 申报 ↗ |
| 2026-05-15 | Power Luke Thomas | 代扣税 (F) | Common Stock | 9,771 | USD 15.25 | USD 149,008 | SEC 申报 ↗ |
| 2026-05-15 | HALBERT DAVID D | 代扣税 (F) | Common Stock | 40,712 | USD 15.25 | USD 620,858 | SEC 申报 ↗ |
| 2026-05-15 | Denton John Russel | 代扣税 (F) | Common Stock | 6,047 | USD 15.25 | USD 92,217 | SEC 申报 ↗ |
| 2026-05-15 | Brille Brian J | 代扣税 (F) | Common Stock | 13,987 | USD 15.25 | USD 213,302 | SEC 申报 ↗ |
| 2026-05-11 | Vacirca Jeff L | 买入 (P) | Common Stock | 31,050 | USD 16.15 | USD 501,457 | SEC 申报 ↗ |
| 2026-03-06 | Spetzler David Baxley | 奖励／授予 (A) | Common Stock | 83,162 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-06 | Power Luke Thomas | 奖励／授予 (A) | Common Stock | 63,971 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-06 | HALBERT DAVID D | 奖励／授予 (A) | Common Stock | 320,112 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-06 | Denton John Russel | 奖励／授予 (A) | Common Stock | 63,971 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-06 | Brille Brian J | 奖励／授予 (A) | Common Stock | 83,162 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-26 | Minor Lloyd | 奖励／授予 (A) | Common Stock | 2,492 | USD 20.06 | USD 49,990 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CAI |
| CIK | 0002019410 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 8071 Services-Medical Laboratories |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 80 transaction lines from 2025-02-27 to 2026-09-22 6 P purchase lines · 7 S sale lines · 67 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.